Covid-19 controversies: the tocilizumab chapter

This editorial summarises research on tocilizumab for Covid-19, discussing possible explanations for discrepant results. It states the totality of randomised data ‘neither overwhelmingly support nor convincingly refute’ its routine use; results of RECOVERY are eagerly awaited.

British Medical Journal